Cécile Colomban1, Joëlle Micallef1, Marie-Noëlle Lefebvre1, Odile Dubourg2, Pierre-Marie Gonnaud3, Tanya Stojkovic2, Elisabeth Jouve1, Olivier Blin1, Jean Pouget4, Shahram Attarian5. 1. Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CIC-CPCET), OrphanDev, CHU La Timone, Marseille, France. 2. Centre de Référence des Maladies Neuromusculaires de Paris Est, Service d'Exploration Fonctionnelle, Neurologie, Hôpital de la Salpétrière, Paris, France. 3. Service d'Explorations et Consultations Neurologiques, Groupe Hospitalier Sud, Hospices Civils de Lyon, France. 4. Centre de Référence des Maladies Neuromusculaires et de la SLA, CHU La Timone, Marseille, France. 5. Centre de Référence des Maladies Neuromusculaires et de la SLA, CHU La Timone, Marseille, France. Electronic address: shahram.attarian@ap-hm.fr.
Abstract
INTRODUCTION: Heterogeneous clinical presentation and gender differences were reported in Charcot-Marie-Tooth disease type 1A (CMT1A). METHODS: This report examined demographic and clinical data collected during a randomised controlled trial, to describe the clinical spectrum of a large and well-defined cohort of CMT1A patients. RESULTS: Among the 189 symptomatic patients screened, three patients (1.6%) reported first symptoms in the upper limbs, which may be misleading when establishing the clinical diagnosis. The quality of life (QoL) of patients was significantly deteriorated compared to the standard population, and slightly better compared to multiple sclerosis patients. According to the literature, patients reported several disorders which may be associated with CMT1A, including auditory dysfunction (7.9%), Carpal Tunnel Syndrome (CTS) (7.9%) or sleep apnoea (4.2%). Compared to available data, we reported more patients with CTS and fewer patients with sleep apnoea. Women were more affected by CTS than men (11% and 2.8%, respectively). Women also reported an earlier onset of symptoms than men (8.6±9.5 years and 13.1±14 years, respectively), higher deterioration of their QoL and higher disability of their upper limb, assessed by Overall Neuropathy Limitation Scale (p=0.023). CONCLUSIONS: This information will be useful for better understanding of this disease and for designing future clinical studies.
RCT Entities:
INTRODUCTION: Heterogeneous clinical presentation and gender differences were reported in Charcot-Marie-Tooth disease type 1A (CMT1A). METHODS: This report examined demographic and clinical data collected during a randomised controlled trial, to describe the clinical spectrum of a large and well-defined cohort of CMT1A patients. RESULTS: Among the 189 symptomatic patients screened, three patients (1.6%) reported first symptoms in the upper limbs, which may be misleading when establishing the clinical diagnosis. The quality of life (QoL) of patients was significantly deteriorated compared to the standard population, and slightly better compared to multiple sclerosispatients. According to the literature, patients reported several disorders which may be associated with CMT1A, including auditory dysfunction (7.9%), Carpal Tunnel Syndrome (CTS) (7.9%) or sleep apnoea (4.2%). Compared to available data, we reported more patients with CTS and fewer patients with sleep apnoea. Women were more affected by CTS than men (11% and 2.8%, respectively). Women also reported an earlier onset of symptoms than men (8.6±9.5 years and 13.1±14 years, respectively), higher deterioration of their QoL and higher disability of their upper limb, assessed by Overall Neuropathy Limitation Scale (p=0.023). CONCLUSIONS: This information will be useful for better understanding of this disease and for designing future clinical studies.
Authors: Maria Nolano; Fiore Manganelli; Vincenzo Provitera; Chiara Pisciotta; Annamaria Stancanelli; Giuseppe Caporaso; Rosa Iodice; Michael E Shy; Lucio Santoro Journal: Neurology Date: 2014-12-24 Impact factor: 9.910
Authors: Sean Ekins; Nadia K Litterman; Renée J G Arnold; Robert W Burgess; Joel S Freundlich; Steven J Gray; Joseph J Higgins; Brett Langley; Dianna E Willis; Lucia Notterpek; David Pleasure; Michael W Sereda; Allison Moore Journal: F1000Res Date: 2015-02-26